全文获取类型
收费全文 | 244073篇 |
免费 | 22532篇 |
国内免费 | 11554篇 |
专业分类
耳鼻咽喉 | 3478篇 |
儿科学 | 4471篇 |
妇产科学 | 3254篇 |
基础医学 | 38184篇 |
口腔科学 | 6384篇 |
临床医学 | 19744篇 |
内科学 | 33731篇 |
皮肤病学 | 4907篇 |
神经病学 | 9383篇 |
特种医学 | 8021篇 |
外国民族医学 | 216篇 |
外科学 | 27634篇 |
综合类 | 40634篇 |
现状与发展 | 64篇 |
预防医学 | 6569篇 |
眼科学 | 3684篇 |
药学 | 17571篇 |
45篇 | |
中国医学 | 6326篇 |
肿瘤学 | 43859篇 |
出版年
2024年 | 167篇 |
2023年 | 3176篇 |
2022年 | 4476篇 |
2021年 | 8154篇 |
2020年 | 7678篇 |
2019年 | 7380篇 |
2018年 | 7524篇 |
2017年 | 8169篇 |
2016年 | 8812篇 |
2015年 | 10056篇 |
2014年 | 15027篇 |
2013年 | 15548篇 |
2012年 | 14239篇 |
2011年 | 15744篇 |
2010年 | 12985篇 |
2009年 | 12704篇 |
2008年 | 13288篇 |
2007年 | 13807篇 |
2006年 | 12661篇 |
2005年 | 11511篇 |
2004年 | 9800篇 |
2003年 | 8514篇 |
2002年 | 7013篇 |
2001年 | 6351篇 |
2000年 | 5322篇 |
1999年 | 4435篇 |
1998年 | 3755篇 |
1997年 | 3492篇 |
1996年 | 3122篇 |
1995年 | 3110篇 |
1994年 | 2784篇 |
1993年 | 2214篇 |
1992年 | 1894篇 |
1991年 | 1711篇 |
1990年 | 1379篇 |
1989年 | 1258篇 |
1988年 | 1209篇 |
1987年 | 957篇 |
1986年 | 848篇 |
1985年 | 1054篇 |
1984年 | 927篇 |
1983年 | 632篇 |
1982年 | 717篇 |
1981年 | 586篇 |
1980年 | 525篇 |
1979年 | 402篇 |
1978年 | 287篇 |
1977年 | 225篇 |
1976年 | 184篇 |
1973年 | 79篇 |
排序方式: 共有10000条查询结果,搜索用时 48 毫秒
11.
12.
13.
14.
目的:探讨赣南地区原发性肺鳞癌患者EGFR和ALK基因突变的特点,科学指导此类患者优选靶向用药。方法:入组73例原发性肺鳞癌病例,采用ARMS-PNA技术检测EGFR基因第18、19、20、21外显子突变,应用不平衡法检测其中60例病例的ALK融合基因,回顾性分析EGFR和ALK基因突变患者的临床病理特征。结果:EGFR基因突变8例,阳性率为10.96%(8/73),4例为L858R突变,3例为19del突变,1例为G719X突变。女性患者突变率(66.67%,2/3)明显高于男性患者(8.57%,6/70)(P=0.030),EGFR基因突变在高龄(≥60岁)、进展期(N_(1-3)、Ⅲ+Ⅳ期)患者中相对较高,但差异无统计学意义(P>0.05)。EGFR基因突变与吸烟史、T分期以及肿瘤分布位置均无相关性(P>0.05);ALK融合基因表达2例,阳性率3.33%(2/60),与患者性别、年龄、吸烟史、TNM分期及肿瘤分布类型等各临床病理特征均无相关性(P>0.05);未发现EGFR和ALK基因共存突变病例。结论:赣南地区原发性肺鳞癌患者EGFR和ALK基因突变率相对不高,EGFR基因突变以L858R和19del突变为主,且好发于女性患者,可能是患者病情进展的预测因子之一。 相似文献
15.
16.
17.
ObjectivesMap regional lymph node metastases for lateralized oral cavity squamous cell carcinoma (OCSCC) and evaluate factors associated with regional metastases and recurrence.Materials and methodsRetrospective cohort study of 715 patients with lateralized OCSCC surgically treated in 1997–2011. Analysis was performed using log-rank, Kaplan-Meier, and multivariable logistic and Cox regression.ResultsRegional metastases were identified in ipsilateral levels IIA (24%), IB (18%), III (13%), V (9%), IV (7%), IA (2%) and IIB (1%) and the contralateral neck (3%). Lymphovascular invasion (LVI) (Hazard Ratio [HR] 2.2, 95% Confidence Interval [CI] 1.2–3.9) and T category (T3 vs. T1: HR 4.1, 95% CI 1.9–9.3; T4 vs. T1: HR 2.3, 95% CI 1.2–4.3) were associated with regional metastases. Most (71%) isolated regional metastatic recurrences were in undissected levels of the neck, including 58% in levels IV and V. Tumors of the hard palate (HR 4.3, 95% CI 1.2–16.1), upper alveolus (HR 3.2, 95% CI 1.0–4.7) or with LVI (HR 2.0, 95% CI 1.0–3.9) were associated with isolated regional recurrence. For upper alveolar/hard palate tumors, depth of invasion (DOI) ≥4 mm (P = .003) and LVI (P = .04) were associated with regional metastases.ConclusionsFor lateralized OCSCC, elective neck dissection of level IIB or the contralateral neck may rarely be needed, but additional surgical or radiation treatment of levels IV and V may be considered based on patient risk factors, including T category 3–4 or LVI. For upper alveolar/hard palate tumors, DOI ≥4 mm is an appropriate threshold for elective neck dissection. 相似文献
18.
《European journal of surgical oncology》2022,48(3):482-491
ObjectiveTo systematically evaluate the clinicopathological and prognostic value of extra-hepatic bile duct resection (EHBDR) in the surgical management of patients with gallbladder carcinoma (GBC), especially in non-jaundiced patients.MethodsPubMed, EMBASE and the Cochrane Library were searched up to March 1st 2021 for comparative studies between bile duct resected and non-resected groups. RevMan5.3 and Stata 13.0 software were used for the statistical analyses.ResultsEHBDR did not correlate with a better overall survival (OS) (P = 0.17) or disease-free survival (P = 0.27). No survival benefit was also observed in patients with T2N1 (P = 0.4), T3N0 (P = 0.14) disease and node-positive patients (P = 0.75), rather, EHBDR was even harmful for patients with T2N0 (P = 0.01) and node-negative disease (P = 0.02). Significantly higher incidences of recurrent disease (P = 0.0007), postoperative complications (P < 0.00001) and positive margins (P = 0.02) were detected in the bile duct-resected group. The duration of postoperative hospital stay between the two groups was comparable (P = 0.58). Selection bias was also detected in our analysis that a significantly higher proportion of advanced lesions with T3-4 or III-IV disease was observed in the bile duct-resected group (P < 0.00001). EHBDR only contributed to a greater lymph yield (P = 0.01).ConclusionEHBDR has no survival advantage for patients with GBC, especially for those with non-jaundiced disease. Considering the unfairness of comparing OS between jaundiced patients receiving EHBDR with non-jaundiced patients without EHBDR, we could only conclude that routine EHBDR in non-jaundiced patients is not recommended and future well-designed studies with more specific subgroup analyses are required for further validation. 相似文献
19.
BackgroundThe Journal of Oral Biosciences is devoted to advancing and disseminating fundamental knowledge concerning every aspect of oral biosciences.HighlightThis review features review articles in the fields of “Extracellular Vesicles,” “Propolis,” “Odontogenic Tumors,” “Periodontitis,” “Periodontium,” “Flavonoids,” “Lactoferrin,” “Dental Plaque,” “Anatomy,” “Induced Pluripotent Stem Cells,” “Bone Cell Biology,” “Dysgeusia,” “Dental Caries,” and “Dental Pulp Cavity,” in addition to the review article by the winners of the “Lion Award” (“Sox9 function in salivary gland development”) presented by the Japanese Association for Oral Biology.ConclusionThese reviews in the Journal of Oral Biosciences have inspired its readers to broaden their knowledge regarding various aspects of oral biosciences. The current editorial review introduces these exciting review articles. 相似文献
20.
尽管嵌合抗原受体(CAR)T细胞治疗在血液系统恶性肿瘤患者中取得了显著的临床疗效,但需要进一步优化。脂质纳米粒(LNP)-信使核糖核酸(mRNA)递送系统作为一种非病毒性基因载体运用于CAR-T细胞治疗研究中,一方面通过LNP将密封蛋白-6 mRNA靶向递送至抗原提呈细胞,从而实现抗原提呈细胞辅助性增强密封蛋白-6靶向的CAR-T细胞的功能,以进一步诱导对实体瘤的清除;另一方面,通过LNP将成纤维细胞激活蛋白(FAP)CARmRNA靶向递送至T细胞,实现体内FAP靶向的CAR-T细胞的制备,以通过阻断心脏纤维化过程达到治疗急性心肌损伤的目的。在CAR-T细胞研究和治疗中,LNP-mRNA递送系统具有不与细胞基因组整合、价格便宜、毒副作用小及可修饰等优点,亦存在蛋白瞬时表达导致调控细胞功能的持久性不足及制备等方面的技术局限性。本文综述了LNP-mRNA递送系统及其在CAR-T细胞治疗中的应用研究。 相似文献